ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  van Beers, Joyce J B C ^a   Willemze, Annemiek ^b   Jansen, Jeroen J ^c   Engbers, Gerard H M ^d   Salden, Martin ^e   Raats, Jos ^f   Drijfhout, Jan W ^b   van der Helm van Mil, Annette H M ^b   Toes, Rene E M ^b   Pruijn, Ger J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d Ssens BV   (Netherlands)

^e Euro Diagnostica AB   (Netherlands)

^f ModiQuest Research   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; AUTOANTIBODY; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; PEPTIDE;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; PEPTIDE LIBRARY; PROTEIN ANALYSIS; PROTEIN IMMOBILIZATION; RHEUMATOID ARTHRITIS; SURFACE PLASMON RESONANCE; AMINO ACID SEQUENCE; BLOOD; EQUIPMENT; GENETIC PROCEDURES; IMMUNOLOGY; METHODOLOGY; MOLECULAR GENETICS; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; TIME;

AMINO ACID SEQUENCE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOSENSING TECHNIQUES; CITRULLINE; DISEASE PROGRESSION; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PEPTIDES, CYCLIC; PRINCIPAL COMPONENT ANALYSIS; SURFACE PLASMON RESONANCE; TIME FACTORS;

EID: 84884765647     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4322     Document Type: Article

References (41)

1. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008, 1143:268-285. 10.1196/annals.1443.013, 19076355.
2. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25:1106-1118. 10.1002/bies.10357, 14579251.
3. Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R, Yamamoto K. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 2006, 65:1013-1020. 10.1136/ard.2005.044743, 1798256, 16449316.
4. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, Moyes D, Taylor PC, Venables PJ. Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R1421-R1429. 10.1186/ar1845, 1297593, 16277695.
5. Vossenaar ER, Després N, Lapointe E, van der Heijden A, Lora M, Senshu T, van Venrooij WJ, Ménard HA. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:R142-R150. 10.1186/ar1149, 400433, 15059278.
6. Burkhardt H, Sehnert B, Bockermann R, Engström A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005, 35:1643-1652. 10.1002/eji.200526000, 15832289.
7. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology (Oxford) 2005, 44:1374-1382.
8. Raijmakers R, van Beers JJ, El-Azzouny M, Visser NF, Božič B, Pruijn GJ, Heck AJ. Elevated levels of fibrinogen-derived endogenous citrullinated peptides in synovial fluid of rheumatoid arthritis patients. Arthritis Res Ther 2012, 14:R114. 10.1186/ar3840, 3446491, 22584083.
9. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, Oosterink E, Božič B, Pruijn GJ. The RA synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen and β-actin. Arthritis Rheum 2013, 65:69-80. 10.1002/art.37720, 23044660.
10. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011, 7:391-398. 10.1038/nrrheum.2011.76, 21647203.
11. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, Frisch M. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006, 8:R133. 10.1186/ar2022, 1779386, 16872514.
12. van der Woude D, Syversen SW, van d V, Verpoort KN, Goll GL, van der Linden MP, van der Helm-van Mil AH, van der Heijde DM, Huizinga TW, Kvien T, Toes RE. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2010, 69:1110-1116. 10.1136/ard.2009.116384, 20439289.
13. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749. 10.1002/art.11223, 14558078.
14. Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard HA, Lora M, Trouw LA, Huizinga TW, Toes RE. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 2011, 70:188-193. 10.1136/ard.2010.131102, 20736390.
15. Ohmura K, Terao C, Maruya E, Katayama M, Matoba K, Shimada K, Murasawa A, Honjo S, Takasugi K, Tohma S, Matsuo K, Tajima K, Yukawa N, Kawabata D, Nojima T, Fujii T, Yamada R, Saji H, Matsuda F, Mimori T. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:2298-2304.
16. Willemze A, Trouw LA, Toes RE, Huizinga TW. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012, 8:144-152. 10.1038/nrrheum.2011.204, 22293763.
17. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010, 69:1333-1337. 10.1136/ard.2009.121160, 20498212.
18. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K, Hirschberg DL, Morris RI, Muller S, Pruijn GJ, van Venrooij WJ, Smolen JS, Brown PO, Steinman L, Utz PJ. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002, 8:295-301. 10.1038/nm0302-295, 11875502.
19. Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueria L, Jakobsson PJ, Lundberg K, Malmström V, Serre G, Holmdahl R, Nystrand M, Klareskog L, Rönnelid J. Validation of a multiplex chip-based for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther 2012, 14:R201. 10.1186/ar4039, 3580513, 23025688.
20. Chandra PE, Sokolove J, Hipp BG, Lindstrom TM, Elder JT, Reveille JD, Eberl H, Klause U, Robinson WH. Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther 2011, 13:R102. 10.1186/ar3383, 3218917, 21702928.
21. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, Edison JD, Gilliland WR, Tibshirani RJ, Norris JM, Holers VM, Robinson WH. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012, 7:e35296. 10.1371/journal.pone.0035296, 3360701, 22662108.
22. Lokate AM, Beusink JB, Besselink GA, Pruijn GJ, Schasfoort RB. Biomolecular interaction monitoring of autoantibodies by scanning surface plasmon resonance microarray imaging. J Am Chem Soc 2007, 129:14013-14018. 10.1021/ja075103x, 17941638.
23. van Beers JJ, Raijmakers R, Alexander LE, Stammen-Vogelzangs J, Lokate AM, Heck AJ, Schasfoort RB, Pruijn GJ. Mapping of citrullinated fibrinogen B-cell epitopes in rheumatoid arthritis by imaging surface plasmon resonance. Arthritis Res Ther 2010, 12:R219. 10.1186/ar3205, 3046532, 21182780.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
25. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes: what can be learned from the Leiden early arthritis clinic?. Rheumatology (Oxford) 2011, 50:93-100.
26. Hiemstra HS, Duinkerken G, Benckhuijsen WE, Amons R, de Vries RR, Roep BO, Drijfhout JW. The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries. Proc Natl Acad Sci USA 1997, 94:10313-10318. 10.1073/pnas.94.19.10313, 23359, 9294207.
27. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163. 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3, 10643712.
28. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, Allaart CF. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008, 58:1293-1298. 10.1002/art.23439, 18438829.
29. Willemze A, Böhringer S, Knevel R, Levarht EW, Stoeken-Rijsbergen G, Houwing-Duistermaat JJ, van der Helm-van Mil AH, Huizinga TW, Toes RE, Trouw LA. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis 2012, 71:268-274. 10.1136/annrheumdis-2011-200421, 21998120.
30. Lundberg K, Bengtsson C, Kharlamova N, Reed E, Jiang X, Kallberg H, Pollak-Dorocic I, Israelsson L, Kessel C, Padyukov L, Holmdahl R, Alfredsson L, Klareskog L. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis 2013, 72:652-658. 10.1136/annrheumdis-2012-201484, 22661643.
31. Montes A, Perez-Pampin E, Calaza M, Gomez-Reino JJ, Gonzalez A. Association of anti-citrullinated vimentin and anti-citrullinated α-enolase antibodies with subsets of rheumatoid arthritis. Arthritis Rheum 2012, 64:3102-3110. 10.1002/art.34569, 22674012.
32. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, Engström A, Venables PJ, Lundeberg J, Holmdahl R, Klareskog L, Malmström V. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009, 68:736-743. 10.1136/ard.2008.091355, 18635594.
33. Fisher BA, Plant D, Brode M, van Vollenhoven RF, Mathsson L, Symmons D, Lundberg K, Rönnelid J, Venables PJ. Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1095-1098. 10.1136/ard.2010.138909, 21367760.
34. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, Alexander C, Hesterberg LK. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal 2012, 70:415-424.
35. van Baarsen LG, Bos WH, Rustenburg F, van der Pouw Kraan TC, Wolbink GJ, Dijkmans BA, van Schaardenburg D, Verweij CL. Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum 2010, 62:694-704. 10.1002/art.27294, 20131234.
36. Wright HL, Bucknall RC, Moots RJ, Edwards SW. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 2012, 51:451-459.
37. Churchman SM, Geiler J, Parmar R, Horner EA, Church LD, Emery P, Buch MH, McDermott MF, Ponchel F. Multiplexing immunoassays for cytokine detection in the serum of patients with rheumatoid arthritis: lack of sensitivity and interference by rheumatoid factor. Clin Exp Rheumatol 2012, 30:534-542.
38. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, Sønderstrup G, Monach P, Drijfhout JW, van Venrooij WJ, Utz PJ, Genovese MC, Robinson WH. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005, 52:2645-2655. 10.1002/art.21269, 16142722.
39. van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, Drijfhout JW, Huizinga TW, Toes RE, Pruijn GJ. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010, 69:1554-1561. 10.1136/ard.2009.124537, 20448290.
40. Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, Stenlund H, Rönnelid J, Klareskog L, Rantapää-Dahlqvist S. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013, 65:899-910. 10.1002/art.37835, 23310951.
41. van de Stadt LA, de Koning MH, van de Stadt RJ, Wolbink G, Dijkmans BA, Hamann D, van Schaardenburg D. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011, 63:3226-3233. 10.1002/art.30537, 21792832.